Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

p53 prevents doxorubicin cardiotoxicity independently of its prototypical tumor suppressor activities

5 Sept 2019

Abstract excerpt

Significance Doxorubicin is a DNA-damaging agent that is highly effective against various types of cancers, but a subset of treated patients develop heart failure for unclear genetic reasons. In the current study using p53 mouse models, low-dose doxorubicin as administered in the clinics surprisingly revealed that the absence of p53 increases susceptibility to doxorubicin cardiotoxicity while a mutant of p53 that...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chemotherapy-induced cardiotoxicity and mitigation
Share to Mitochondrial Function and Pathology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31488712
DOI: 10.1073/pnas.1904979116

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

p53 prevents doxorubicin cardiotoxicity independently of its prototypical tumor suppressor activitiesPMID 31488712Read ↗

p53 at the Crossroads between Doxorubicin-Induced Cardiotoxicity and Resistance: A Nutritional Balancing ActSemantic proximity Read ↗

p53 contributes to cardiovascular diseases via mitochondria dysfunction: A new paradigmSemantic proximity Read ↗

Transcriptomic profiling reveals p53 as a key regulator of doxorubicin-induced cardiotoxicitySemantic proximity Read ↗

Anthracycline-mediated cardiomyopathy: Basic molecular knowledge for the cardiologistSemantic proximity Read ↗

Doxorubicin-Induced p53 Interferes with Mitophagy in Cardiac FibroblastsSemantic proximity Read ↗

The Abl1 tyrosine kinase is a key player in doxorubicin-induced cardiomyopathy and its p53/p73 cell death mediated signaling differs in atrial and ventricular cardiomyocytesSemantic proximity Read ↗

Mitochondria and Doxorubicin-Induced Cardiomyopathy: A Complex InterplaySemantic proximity Read ↗

Qishen Granule Protects against Doxorubicin‐Induced Cardiotoxicity by Coordinating MDM2‐p53‐Mediated Mitophagy and Mitochondrial BiogenesisSemantic proximity Read ↗

Doxorubicin cardiotoxicity and target cells: a broader perspectiveSemantic proximity Read ↗

Review on the Role of Epigenetic Modifications in Doxorubicin-Induced CardiotoxicitySemantic proximity Read ↗

Transcriptomic Insights into Early Diagnosis of Doxorubicin-Induced Cardiotoxicity in a Rat ModelSemantic proximity Read ↗

MicroRNAs in doxorubicin-induced cardiotoxicity: The DNA damage responseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.